{'fraction_non_alphanumeric': 0.031936127744510975, 'fraction_numerical': 0.003992015968063872, 'mean_word_length': 5.435897435897436, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Methotrexate and melanoma‐specific mortality

Methotrexate (MTX) exposure has been linked to an increased risk for cutaneous malignant melanoma (CMM).1 In a previous publication, a small risk increase for CMM among MTX-exposed individuals compared to MTX-unexposed age- and sex-matched individuals was observed.2 However, the risk increase had a negligible clinical relevance which is reassuring to physicians in everyday clinical practice. This article is protected by copyright. All rights reserved.